Clinical Trial Update: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates cetuximab with or without weekly paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma who prog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Conditions: Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING